First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination

Hepatocellular carcinoma (HCC) is an aggressive malignancy accounting for 90% of primary liver malignancies. Therapeutic options for HCC are primarily based on the baseline functional status, the extent of disease at presentation and the underlying liver function that is clinically evaluated by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tella, Sri Harsha, Kommalapati, Anuhya, Mahipal, Amit, Jin, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220769/
https://www.ncbi.nlm.nih.gov/pubmed/35740326
http://dx.doi.org/10.3390/biomedicines10061304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220769/
https://www.ncbi.nlm.nih.gov/pubmed/35740326
http://dx.doi.org/10.3390/biomedicines10061304

Ejemplares similares